<p>Through clinical trials focused on molecularly guided therapy in pediatric cancers (<a href="https://clinicaltrials.gov/ct2/show/NCT01355679">NCT01355679</a>, <a href="https://clinicaltrials.gov/ct2/show/NCT01802567">NCT01802567</a>, <a href="https://clinicaltrials.gov/ct2/show/NCT02162732">NCT02162732</a>), the Beat Childhood Cancer Consortium performed paired tumor/normal whole exome sequencing and/or tumor mRNA sequencing for 202 pediatric or adolescent young adult patients with rare, relapsed and refractory cancers (including neuroblastoma, Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, ependymoma, glioma, and other rare solid tumors). A subset of these patients had multiple biopsies sequenced, including longitudinal profiling.</p>

Genomic Profiling of Relapsed and Refractory Childhood Cancers

Neoplasms study with RNA-Seq, WXS data on dbGaP (202 participants)